Innovation
rd
On 23 December 2014
Summary
Large Degree of Innovation in NSCLC Pipeline
The NSCLC pipeline currently has 389 products in active development across all stages, but a
stark contrast between the mechanisms of action employed in the current market and the
pipeline is evident. Where the market comprises primarily ineffective chemotherapies that
target tubulin or DNA replication, the pipeline shows an incredibly diverse range of therapies
targeting multiple signaling pathways and molecules integral to cancer development. This
diversity is partially due to the presence of 122 first-in-class products, which accounts for 38%
of the overall pipeline therapies that disclosed their target. In an industry, market and
development landscape that favors first-in-class over non-first-in-class development in many
ways, such as through faster approval or greater revenue, this finding has strategic implications
for a wide array of market participants, both large and small. Despite a high attrition rate in
NSCLC, first-in-class therapies that reach the market have the potential to transform and
improve the NSCLC treatment landscape.
Alignment of First-in-Class Molecular Target with Disease Causation
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
The method of characterizing NSCLC tumors is currently shifting from the traditional histologybased characterization to a more specific molecule-based method of characterization. This has
resulted in the identification of key oncogenic mutations in NSCLC and has coincided with the
rise of targeted pipeline therapies, which are designed to target proteins in signaling pathways
that are frequently mutated, amplified or overexpressed in NSCLC. Aligning the molecular
target with disease-causing signaling pathways and frequently mutated pathways therapies can
benefit from reduced systemic cytotoxic effects while still inhibiting tumor-promoting signaling.
Therefore, targeted therapies often display superior safety and efficacy to chemotherapies.
GBI Researchs proprietary analysis showed substantial variation in how well NSCLC first-in-class
targets align to frequent gene mutations. Further in-depth analysis identified the most
promising first-in-class targets based on various scientific and clinical parameters. Examining
scientific and clinical data of promising first-in-class targets showed that first-in-class status is
not, in its own right, enough for a successful product; however, the first-in-class products
substantiated by scientific and clinical evidence will be exciting future prospects with the
potential to transform the NSCLC market.
First-in-Class Products in Licensing and Co-development Deals
The NSCLC deals landscape appears relatively quiet for such a large indication. However,
analysis showed that of the therapies with disclosed deal values there is significant range in the
value of NSCLC deals. Concerning first-in-class specifically, only five licensing or co-development
deals have been made since 2006. Despite the low sample size, it is clear that the first-in-class
NSCLC products offer an attractive investment prospect as they command much higher deal
values and, on average, deals occur earlier in development compared to non-first-in-class
counterparts. Both trends were substantiated by industry-wide data that showed that,
particularly in Phase I, first-in-class products would attract larger mean and median total deal
values. The data highlight that the first-in-class deals landscape is different and indicates a
greater chance of becoming much more lucrative than the deals landscape for addition-to-class
or advance-in-class therapies.
A total of 117 first-in-class products that are currently in development have not yet been
entered into a licensing or co-development deal. In a transforming market that will favor
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
innovative, targeted therapies with a strong clinical record, there are numerous opportunities
for strategic alliances to bolster a first-in-class portfolio or fund clinical development. Although
not all are aligned to disease-causing signaling pathways, many are supported by robust
scientific and clinical data, making them attractive prospects as both therapeutics and
investment opportunities.
Reasons to buy
The report will enable business development and enable marketing executives to strategize
their product launches by allowing them to Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
Table of Content
1.1 List of Tables 2
1.2 List of Figures 2
2 Executive Summary 4
2.1 A High Degree of First-In-Class Innovation in an Active Pipeline 4
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
List Of Tables
List Of Figures
Report Price:
Licence Type
Price
$ 6995
Site Licence
$ 13990
$ 20985
Related Reports:
Emesis (Vomiting) - Pipeline Review, H2 2014
Myasthenia Gravis - Pipeline Review, H2 2014
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014
Malnutrition Global Clinical Trials Review, H2, 2014
Kaposis Sarcoma Global Clinical Trials Review, H2, 2014
MediPoint: Craniomaxillofacial Devices - US Analysis and Market Forecasts
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2014
High-Grade Glioma - Pipeline Review, H2 2014
Raynauds Disease - Pipeline Review, H2 2014
Japanese Encephalitis - Pipeline Review, H2 2014
You can order this report by calling on +91 - 998 7295 242 or mail us
your contact details at contact@jsbmarketresearch.com
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along
with providing in-depth analysis though reports, JSB market research also provides regular
updates of the market though newsletters. Our reports are a well-researched work of market
researchers with an extensive knowledge and a good level of market experience.
To know more on Frontier Pharma: Non-Small Cell Lung Cancer - Identifying and
Commercializing First-in-Class Innovation
http://www.jsbmarketresearch.com/healthcare-medical/r-frontier-pharmanon-small-cell-lung-cancer-identifying-and-commercializing-first-in-classinnovation-138191